Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• Lafora disease (LD) is a fatal, inherited childhood epilepsy.
• It is characterized by the accumulation of Lafora bodies (LBs), insoluble polysaccharide deposits.
• Genetic mutations in EPM2A or EPM2B genes cause LD.

Purpose of the Study:

• To investigate human pancreatic α-amylase as a therapeutic agent for degrading Lafora bodies.
• To develop and evaluate an antibody-enzyme fusion (VAL-0417) for targeted LB degradation in LD.

Main Methods:

• Human pancreatic α-amylase was fused to a cell-penetrating antibody fragment to create VAL-0417.
• LB degradation was assessed in vitro.
• VAL-0417 efficacy was evaluated in vivo using Epm2a-/- mice, a model for LD.
• Metabolomics and multivariate analysis were used to assess metabolic changes.

Main Results:

• Human pancreatic α-amylase demonstrated the ability to degrade Lafora bodies.
• VAL-0417 effectively degraded Lafora bodies in vitro.
• In vivo studies showed VAL-0417 significantly reduced LB loads in Epm2a-/- mice.
• Metabolic profiling revealed VAL-0417 treatment normalized the metabolic phenotype in treated mice.

Conclusions:

• VAL-0417 is a potent therapeutic agent for degrading Lafora bodies.
• This antibody-enzyme fusion shows significant promise for treating Lafora disease.
• VAL-0417 represents a potential precision therapy platform for intractable epilepsies.